Impel Neuropharma, Inc.

SEATTLE, WA 98122
http://www.impelneuropharma.com
6 Employees

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $3.63MM
First Award Date 07/01/09
Most Recent Award Date 07/28/17

Key Personnel

Last Name Name Awards Contact
Ho Rodney J.Y. Ho 1 Message
Hoekman John Hoekman 3 Message
Brunelle Alan Brunelle 2
Hoekman John Hoekman 2
Ho Rodney J.Y. Ho 1

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-250
Budget: 07/28/17 - 03/31/18

? DESCRIPTION (provided by applicant): Impel NeuroPharma is developing a nose-to-brain drug delivery device to enable drugs to bypass the blood brain barrier (BBB) in humans. This Phase II SBIR aims to develop robust, non-custom, and affordable devices for use in preclinical studies that makes the technology more accessible to researchers eve...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-250
Budget: 04/01/16 - 03/31/17

? DESCRIPTION (provided by applicant): Impel NeuroPharma is developing a nose-to-brain drug delivery device to enable drugs to bypass the blood brain barrier (BBB) in humans. This Phase II SBIR aims to develop robust, non-custom, and affordable devices for use in preclinical studies that makes the technology more accessible to researchers eve...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-134
Budget: 11/01/13 - 10/31/14

DESCRIPTION (provided by applicant): Animal models of disease are transforming preclinical research, allowing critical insights into disease mechanisms and evaluation of new therapeutics. While the utility and availability of animal models in research is swiftly expanding often the research tools necessary to optimally exploit these models are...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-134
Budget: 11/20/12 - 10/31/13

DESCRIPTION (provided by applicant): Animal models of disease are transforming preclinical research, allowing critical insights into disease mechanisms and evaluation of new therapeutics. While the utility and availability of animal models in research is swiftly expanding often the research tools necessary to optimally exploit these models are...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 02/15/12 - 07/31/12

DESCRIPTION (provided by applicant): The primary goal of this proposal is to develop opioid peptide aerosol-compatible formulations and an intranasal drug delivery system to deliver mu/delta opioid peptides to the central nervous system (CNS) in effective concentrations as the first step in developing a new class of safe and efficacious pain med...

Phase 2 SBIR

Agency: Chemical and Biological Defense Program
Topic: CBD10-109
Budget: 07/12/11 - 12/09/13

Technical Abstract Impel NeuroPharma has developed a novel non-invasive delivery system, the POD device that targets drug to the upper third of the nasal cavity which results in direct and rapid transport of drug to the CNS via the olfactory perineural pathways, effectively bypassing the BBB. In Phase I of this research contract Impel successf...

Phase 1 SBIR

Agency: Chemical and Biological Defense Program
Topic: CBD10-109
Budget: 07/12/10 - 01/11/11

This program plans to develop a drug delivery system that provides maximum oxime drug exposure and improve cholinesterase reactivation in the brain and tissues of central nervous system (CNS) of a warfighter after exposure to organophosphate (OP) poisoning. The greatest need for improvement in cholinesterase reactivation is the ability to deliv...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-432
Budget: 07/01/10 - 06/30/11

DESCRIPTION (provided by applicant): This program plans to develop a drug delivery system that provides maximum drug exposure and suppress residual human immunodeficiency virus (HIV)* in the brain and tissues of central nervous system (CNS). The advent of highly active antiretroviral combination drug therapies (HAART) has reduced plasma virus co...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-432
Budget: 07/01/09 - 06/30/10

DESCRIPTION (provided by applicant): This program plans to develop a drug delivery system that provides maximum drug exposure and suppress residual human immunodeficiency virus (HIV)* in the brain and tissues of central nervous system (CNS). The advent of highly active antiretroviral combination drug therapies (HAART) has reduced plasma virus co...